Abstract:Objectives: As a part of NHS' Innovation and Technology Payment programme (ITP), pregnant women were offered Placental Growth Factor (PLGF)-based testing to help rule out pre-eclampsia (PET) - a serious condition that affects approximately 2.3% of the female population. The study was aimed to evaluate the implementation of PLGF-based testing at United Lincolnshire Trust Hospitals (ULHT). Study design: The soluble FMS like Tyrosine kinase 1/placental growth factor (sFlt-1/PLGF) ratio test was launched at ULHT on 8th October 2020. The project involved a review of an electronic maternity database (MEDWAY) for all women who had sFLT-1/PLGF ratio test performed at ULHT over a 5-month period (October 2020-February 2021). The sFlt-1/PLGF ratio was recorded alongside clinical outcome. Women were classified as low, moderate, and high risk for development of PET if the sFlt-1/PLGF ratio was ≤ 38, 39-84 and ≥ 85 respectively. Reasons for admission were further investigated and adherence to the sFLT-1/PLGF protocol was monitored to evaluate staff performance. Data was then statistically analysed with χ2 and T-test for categorical and continuous variables respectively. Finally, sensitivity and specificity of the sFLT-1/PLGF was assessed with an ROC curve. Results: A total of 236 women had sFlt-1/PLGF ratio test performed in a five-month period. A two-time point analysis (a "during implementation" and "post implementation phase") showed a significant decrease in the admission rates in the post-implementation phase in low-risk group (28.5% during implementation vs 11.3% post-implementation, P < 0.05). Further analysis showed greater staff adherence to the sFLT-1/PLGF protocol in the post-implementation period. The high-risk group demonstrated shorter time from test to delivery, earlier gestational age at delivery and lower birth weight (P < 0.05). Conclusions: The study outcomes resulted in a successful submission of a business case. Successful triage of low-risk women at the point where historically admissions were considered reduced clinical workload and enabled better utilisation of resources by allowing focussed care on high-risk women for an optimal maternal and perinatal outcome.

Enhancing Pregnancy Care: Harnessing Label‐Free Immunosensors for Pre‐Eclampsia Detection Using PdNPs/Poly(3,5‐Diaminobenzoic Acid) Modified Glassy Carbon Electrodes

Polymeric optical fiber biosensor with PAMAM dendrimer-based surface modification and PlGF detection for pre-eclampsia diagnosis

Sensitive Fluorescence Analysis of Pregnancy Plasma Associated Protein A in Amniotic Fluid Based on the Plasma Superstructure Enhanced Carbon Polymer Dots

Systematic design and evaluation of aptamers for VEGF and PlGF biomarkers of Preeclampsia

Bowtie Nanoantenna LSPR Biosensor for Early Prediction of Preeclampsia

Target-mediated silver deposition-based electrochemical biosensor for highly sensitive detection of human chorionic gonadotropin

Predicting late-onset preeclampsia by detecting ELABELA content using an immunochromatographic colloidal gold test strip: Blood ELABELA content predicts the risk of pre-eclampsia

Label-Free Immunosensor Based on Pd Nanoplates for Amperometric Immunoassay of Alpha-Fetoprotein

Disposable and cost-effective label-free electrochemical immunosensor for prolactin based on bismuth sulfide nanorods with polypyrrole

Sandpaper-templated Stretchable Immunosensing Electrodes for Sub-picomolar Progesterone Detection

Implementing placental-growth-factor (PLGF) measurements in suspected pre-eclampsia----Challenges in clinical practice

Long-term monitoring of blood biomarkers related to intrauterine growth restriction using AgNPs SERS tags-based lateral flow assay

Plasmonic pregnancy detector: enhancing sensitivity with SPR sensor

Automated electrochemiluminescence immunoassay for serum PlGF levels in women with singleton pregnancy at 9-13 weeks of gestation predicts preterm preeclampsia: a retrospective cohort study

Electro-responsive Molecularly Imprinted Polymers (E-MIPs) for Rapid Detection of Progesterone in Human Serum Samples

Aptamer-based label-free impedimetric biosensor for detection of progesterone

Electroactive Molecularly Imprinted Polymer Nanoparticles (eMIPs) for Label-free Detection of Glucose: Toward Wearable Monitoring

Electrochemiluminescence immunoassay of human chorionic gonadotropin using silver carbon quantum dots and functionalized polymer nanospheres

Liquid crystal biosensor based on AuNPs signal amplification for detection of human chorionic gonadotropin

Colorimetric Aptasensor for Progesterone Detection Based on Surfactant-Induced Aggregation of Gold Nanoparticles

Label-free electrochemical biosensor based on dual amplification of gold nanoparticles and polycaprolactones for CEA detection